RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing […]
Rakovina Therapeutics Announces Strategic Pivot to AI
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical […]
Tyson Foods Announces Second Quarter Earnings Conference Call and Webcast
SPRINGDALE, Ark., March 27, 2024 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN) will release second quarter 2024 financial results […]
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports […]
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the […]
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in […]
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic […]
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected […]
Capital Southwest Receives Affirmed Investment Grade Rating from Fitch Ratings
DALLAS, March 27, 2024 (GLOBE NEWSWIRE) — Capital Southwest Corporation (“Capital Southwest”) (Nasdaq: CSWC), an internally managed business development company […]
Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat
SAN MATEO, Calif., March 27, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing […]
